Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
:CDXS
CDXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.90 - $6.08
Previous CloseN/A
Volume271.47K
Average Volume (3M)891.82K
Market Cap
$242.74M
Enterprise Value$220.89M
Total Cash (Recent Filing)$59.78M
Total Debt (Recent Filing)$59.50M
Price to Earnings (P/E)―
Beta2.67
Next Earnings
Aug 13, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding82,844,850
10 Day Avg. Volume895,310
30 Day Avg. Volume891,817
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue4.43
Enterprise Value/Gross Profit6.42
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$5.88Price Target Upside100.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Contracts And PartnershipsThe company secured the first revenue-generating contract for the ECO Synthesis Innovation Lab and met industrial grade criteria across first-generation enzymes.
Customer EngagementCustomer interest continues to gain steam as Codexis announced the first revenue-generating contract for ECO Synthesis, with more to come throughout the year.
Bears Say
Financial ResultsQ4 revenues of $21.5M missed consensus estimates of $27.4M.
Revenue PerformanceRevenues of $7.5M were 56% lower year-over-year, missing expectations by $2.2M.
Codexis News
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $1.90 and its highest was $6.08 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $242.74M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Aug 13, 2025 which is in 5 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on May 14, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.237 by -$0.013.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.19.
How many shares outstanding does Codexis have?
Codexis has 82,844,850 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.237. Following the earnings report the stock price went up 1.619%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
Codexis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.88 (100.68% Upside)
$5.88 (100.68% Upside)
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.4%
Last 30 Days ▲ 18.7%
Last 30 Days ▲ 18.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.18%
12-Months-Change
Fundamentals
Return on Equity
-115.53%
Trailing 12-Months
Asset Growth
-13.82%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. (CDXS) is a biotechnology company that focuses on the development and commercialization of enzymes for a wide range of applications. Operating primarily in the biopharmaceutical and industrial sectors, Codexis utilizes its proprietary CodeEvolver® platform technology to engineer enzymes that enhance the efficacy and efficiency of pharmaceutical manufacturing, food processing, and other industrial processes. The company aims to provide sustainable solutions that improve product quality and reduce environmental impact.
CDXS Company Deck
CDXS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Despite challenges such as a significant year-over-year revenue decline and increased net loss, Codexis maintains a strong financial position and projects future growth driven by advancements in its ecosynthesis platform and machine learning capabilities. The sentiment remains cautiously positive due to strategic progress in key areas.View all CDXS earnings summariesCDXS Stock 12 Month Forecast
Average Price Target
$5.88
▲(100.68% Upside)
Technical Analysis
Foghorn Therapeutics
―
Inhibikase Therapeutics
―
Atea Pharmaceuticals
―
Terns Pharmaceuticals
―
Nuvectis Pharma
―
Ownership Overview
17.79% Insiders
18.60% Mutual Funds
0.84% Other Institutional Investors
52.33% Public Companies and
Individual Investors